Altogether, these results show that the pharmacological inhibition of the EGFR/mTOR/HIF-1 axis has an effective anti-tumor activity in a resistant model of HNSCC cell line, in vitro and in vivo. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.